Orbis Biosciences and Daré Bioscience Collaborate to Advance Innovation for Women's Reproductive Health
Orbis Biosciences and Daré Bioscience Collaborate to Advance Innovation for Women's Reproductive Health
LENEXA, Kan., March 12, 2018 /PRNewswire/ -- Orbis Biosciences, Inc. announced today it has granted Daré Bioscience, Inc. an exclusive option to license worldwide rights to Orbis' long-acting contraceptive products. This agreement leverages Orbis' Stratµm(TM) technology to create an etonogestrel contraceptive for 6- and 12-month durations. The agreement includes pre-clinical studies and the option to enter into a license agreement for clinical development. Financial terms were not disclosed.
"Our long-acting contraceptive products were developed to fill a gap in the options currently available to women. We are excited by Daré's commitment to developing novel women's health products," said Maria Flynn, CEO and President of Orbis Biosciences.
"Orbis's products fit Daré's commitment to advance innovative products for women's reproductive health. We are dedicated to finding the best products and cultivating them for the United States' contraceptive and sexual-health needs," said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
About Daré Bioscience -Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel and differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Daré currently has two product candidates in clinical development. The first is Ovaprene(TM), a non-hormonal monthly contraceptive ring intended to provide protection over multiple weeks between menses. The second is SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder. SST-6007 incorporates sildendafil, the same active ingredient in Viagra(®), in a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. The company is headquartered in San Diego. For more information please visit www.darebioscience.com.
About Orbis Biosciences - Orbis is a pharmaceutical drug delivery manufacturing technology company focused on licensing its technology to companies to optimize their product portfolios. Orbis develops customized formulations and intellectual property for pharmaceutical product manufacture, leveraging their novel Precision Particle Fabrication(®) technology platforms: Optimµm(®) precision encapsulation for oral delivery, Stratµm(TM) precision encapsulation for injectable delivery, and the Unisun(®) platform for enabling sustained-release otic therapies. Providing industry innovation, the company offers cost-effective reformulation pathways to improve pharmaceutical products for improved health outcomes. For more information about Orbis, visit orbisbio.com.
CONTACT: Media Contact: Cat Shoults, (913-544-1199), cat@orbisbio.com
View original content with multimedia:http://www.prnewswire.com/news-releases/orbis-biosciences-and-dare-bioscience-collaborate-to-advance-innovation-for-womens-reproductive-health-300612060.html
SOURCE Orbis Biosciences
